Sandbox Reserved 1644
From Proteopedia
(Difference between revisions)
Line 77: | Line 77: | ||
<p align="justify">The '''active site''' represent by 2x36 is composed of''' six [https://en.wikipedia.org/wiki/Protomer protomers]''' in the asymmetric unite. One protomer counts nine [https://en.wikipedia.org/wiki/Beta_sheet b-strands] and seven [https://en.wikipedia.org/wiki/Alpha_helix a-helices]. An analysis of the complex’ structure suggested that '''two pair of protomers''' form A:B and C:D dimers and that the '''two''' remaining ones remain '''uncoupled'''. The dimer interface A:B/C:D is mostly linked by one another through '''hydrophilic interactions''', where the a1-helix is packed against the b3-strand and the loop between b7 and b8 makes inter-subunit contacts with b2<ref>PMID: 20222013</ref>. | <p align="justify">The '''active site''' represent by 2x36 is composed of''' six [https://en.wikipedia.org/wiki/Protomer protomers]''' in the asymmetric unite. One protomer counts nine [https://en.wikipedia.org/wiki/Beta_sheet b-strands] and seven [https://en.wikipedia.org/wiki/Alpha_helix a-helices]. An analysis of the complex’ structure suggested that '''two pair of protomers''' form A:B and C:D dimers and that the '''two''' remaining ones remain '''uncoupled'''. The dimer interface A:B/C:D is mostly linked by one another through '''hydrophilic interactions''', where the a1-helix is packed against the b3-strand and the loop between b7 and b8 makes inter-subunit contacts with b2<ref>PMID: 20222013</ref>. | ||
- | As all LonA proteins, ''h''Lon catalytic activity relies on a '''Ser-Lys dyad'''. Ser855 on a2 conducts the catalytic cleavage with the assistance of Lys898 on a3 through their [https://en.wikipedia.org/wiki/Hydrogen_bond hydrogen-bonding]. The lysine works as a general [https://en.wikipedia.org/wiki/Base_(chemistry) base] along with Thr880 which, in their deprotonated form, abstract the proton from the [https://en.wikipedia.org/wiki/Nucleophile nucleophilic] serine. Those three residues constitute the <scene name='86/868177/Hlonp_catalytic_core/1'>catalytic core</scene>. A characteristic of ''h''LonP is that the [https://en.wikipedia.org/wiki/310_helix 3(10)] helix at the N-terminal end of a2 is able to bring an '''additional residue into the active site''', Asp852. This most likely enables Lys898 [https://en.wikipedia.org/wiki/Acid_dissociation_constant pKa] lowering by creating a [https://en.wikipedia.org/wiki/Hydrophobe hydrophobic] environment, and thus, prevents the dyad to cut off protein substrates. This catalytic '''inactive form''' is also supported by the Asp852 and Trp770 residues that contribute to the catalytic site obstruction. Asp852 removal from the active site through conformational changes enables ''h''Lon to reach an open state that can hydrolyze protein substrate through ATP consumption<ref>PMID: 20222013</ref>.</p> | + | As all LonA proteins, ''h''Lon catalytic activity relies on a '''Ser-Lys dyad'''. Ser855 on a2 conducts the catalytic cleavage with the assistance of Lys898 on a3 through their [https://en.wikipedia.org/wiki/Hydrogen_bond hydrogen-bonding]. The lysine works as a general [https://en.wikipedia.org/wiki/Base_(chemistry) base] along with Thr880 which, in their deprotonated form, abstract the proton from the [https://en.wikipedia.org/wiki/Nucleophile nucleophilic] serine. Those three residues constitute the <scene name='86/868177/Hlonp_catalytic_core/1'>catalytic core</scene>. A characteristic of ''h''LonP is that the [https://en.wikipedia.org/wiki/310_helix 3(10)] helix at the N-terminal end of a2 is able to bring an '''additional residue into the active site''', Asp852. This most likely enables Lys898 [https://en.wikipedia.org/wiki/Acid_dissociation_constant pKa] lowering by creating a [https://en.wikipedia.org/wiki/Hydrophobe hydrophobic] environment, and thus, prevents the dyad to cut off protein substrates. This catalytic '''inactive form''' is also supported by the Asp852 and Trp770 residues that contribute to the <scene name='86/868177/Hlonp_closed_catalitic_core/1'>catalytic site obstruction</scene>. Asp852 removal from the active site through conformational changes enables ''h''Lon to reach an open state that can hydrolyze protein substrate through ATP consumption<ref>PMID: 20222013</ref>.</p> |
Revision as of 20:05, 17 January 2021
This Sandbox is Reserved from 26/11/2020, through 26/11/2021 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1643 through Sandbox Reserved 1664. |
To get started:
More help: Help:Editing |
2x36 - Structure of the proteolytic domain of the
|
References
- ↑ Bota, Daniela A., and Kelvin J. A. Davies. “Mitochondrial Lon Protease in Human Disease and Aging: Including an Etiologic Classification of Lon-Related Diseases and Disorders.” Free Radical Biology & Medicine 100 (November 2016): 188–98. https://doi.org/10.1016/j.freeradbiomed.2016.06.031.
- ↑ Bota, Daniela A., and Kelvin J. A. Davies. “Mitochondrial Lon Protease in Human Disease and Aging: Including an Etiologic Classification of Lon-Related Diseases and Disorders.” Free Radical Biology & Medicine 100 (November 2016): 188–98. https://doi.org/10.1016/j.freeradbiomed.2016.06.031.
- ↑ Lu, Bin. “Mitochondrial Lon Protease and Cancer.” Advances in Experimental Medicine and Biology 1038 (2017): 173–82. https://doi.org/10.1007/978-981-10-6674-0_12.
- ↑ Bota, Daniela A., and Kelvin J. A. Davies. “Mitochondrial Lon Protease in Human Disease and Aging: Including an Etiologic Classification of Lon-Related Diseases and Disorders.” Free Radical Biology & Medicine 100 (November 2016): 188–98. https://doi.org/10.1016/j.freeradbiomed.2016.06.031.
- ↑ García-Nafría, Javier, Gabriela Ondrovičová, Elena Blagova, Vladimir M Levdikov, Jacob A Bauer, Carolyn K Suzuki, Eva Kutejová, Anthony J Wilkinson, and Keith S Wilson. “Structure of the Catalytic Domain of the Human Mitochondrial Lon Protease: Proposed Relation of Oligomer Formation and Activity.” Protein Science : A Publication of the Protein Society 19, no. 5 (May 2010): 987–99. https://doi.org/10.1002/pro.376.
- ↑ Lu, Bin. “Mitochondrial Lon Protease and Cancer.” Advances in Experimental Medicine and Biology 1038 (2017): 173–82. https://doi.org/10.1007/978-981-10-6674-0_12.
- ↑ « The N-terminal domain plays a crucial role in the structure of a full-length human mitochondrial Lon protease | Scientific Reports ». Consulté le 13 janvier 2021. https://www.nature.com/articles/srep33631.
- ↑ He, Lihong, Dongyang Luo, Fan Yang, Chunhao Li, Xuegong Zhang, Haiteng Deng, et Jing-Ren Zhang. « Multiple domains of bacterial and human Lon proteases define substrate selectivity ». Emerging Microbes & Infections 7 (17 août 2018). https://doi.org/10.1038/s41426-018-0148-4.
- ↑ Kutejová, Eva. « Mitochondrial Lon protease-unique structure and essential function in mammalian cells ». Integrative Cancer Science and Therapeutics 5, nᵒ 6 (2018). https://doi.org/10.15761/ICST.1000296.
- ↑ Voos, Wolfgang, et Karen Pollecker. « The Mitochondrial Lon Protease: Novel Functions off the Beaten Track? » Biomolecules 10, nᵒ 2 (7 février 2020). https://doi.org/10.3390/biom10020253.
- ↑ He, Lihong, Dongyang Luo, Fan Yang, Chunhao Li, Xuegong Zhang, Haiteng Deng, et Jing-Ren Zhang. « Multiple domains of bacterial and human Lon proteases define substrate selectivity ». Emerging Microbes & Infections 7 (17 août 2018). https://doi.org/10.1038/s41426-018-0148-4.
- ↑ Lu, Bin, Swati Yadav, Parul G. Shah, Tong Liu, Bin Tian, Sebastian Pukszta, Nerissa Villaluna, et al. « Roles for the Human ATP-Dependent Lon Protease in Mitochondrial DNA Maintenance ». Journal of Biological Chemistry 282, nᵒ 24 (15 juin 2007): 17363‑74. https://doi.org/10.1074/jbc.M611540200.
- ↑ Kereiche S, Kovacik L, Bednar J, Pevala V, Kunova N, Ondrovicova G, Bauer J, Ambro L, Bellova J, Kutejova E, Raska I. The N-terminal domain plays a crucial role in the structure of a full-length human mitochondrial Lon protease. Sci Rep. 2016 Sep 16;6:33631. doi: 10.1038/srep33631. PMID:27632940 doi:http://dx.doi.org/10.1038/srep33631
- ↑ Garcia-Nafria J, Ondrovicova G, Blagova E, Levdikov VM, Bauer JA, Suzuki CK, Kutejova E, Wilkinson AJ, Wilson KS. Structure of the catalytic domain of the human mitochondrial Lon protease: proposed relation of oligomer formation and activity. Protein Sci. 2010 May;19(5):987-99. PMID:20222013 doi:10.1002/pro.376
- ↑ Garcia-Nafria J, Ondrovicova G, Blagova E, Levdikov VM, Bauer JA, Suzuki CK, Kutejova E, Wilkinson AJ, Wilson KS. Structure of the catalytic domain of the human mitochondrial Lon protease: proposed relation of oligomer formation and activity. Protein Sci. 2010 May;19(5):987-99. PMID:20222013 doi:10.1002/pro.376
- ↑ Garcia-Nafria J, Ondrovicova G, Blagova E, Levdikov VM, Bauer JA, Suzuki CK, Kutejova E, Wilkinson AJ, Wilson KS. Structure of the catalytic domain of the human mitochondrial Lon protease: proposed relation of oligomer formation and activity. Protein Sci. 2010 May;19(5):987-99. PMID:20222013 doi:10.1002/pro.376
- ↑ Wang, N, S Gottesman, M C Willingham, M M Gottesman, and M R Maurizi. “A Human Mitochondrial ATP-Dependent Protease That Is Highly Homologous to Bacterial Lon Protease.” Proceedings of the National Academy of Sciences 90, no. 23 (December 1, 1993): 11247–51. https://doi.org/10.1073/pnas.90.23.11247.
- ↑ Bota, Daniela A., and Kelvin J. A. Davies. “Mitochondrial Lon Protease in Human Disease and Aging: Including an Etiologic Classification of Lon-Related Diseases and Disorders.” Free Radical Biology & Medicine 100 (November 2016): 188–98. https://doi.org/10.1016/j.freeradbiomed.2016.06.031.
- ↑ Bota, Daniela A., and Kelvin J. A. Davies. “Mhttps://proteopedia.org/wiki/skins/common/images/button_extlink.pngitochondrial Lon Protease in Human Disease and Aging: Including an Etiologic Classification of Lon-Related Diseases and Disorders.” Free Radical Biology & Medicine 100 (November 2016): 188–98. https://doi.org/10.1016/j.freeradbiomed.2016.06.031.
- ↑ Bota, Daniela A., and Kelvin J. A. Davies. “Lon Protease Preferentially Degrades Oxidized Mitochondrial Aconitase by an ATP-Stimulated Mechanism.” Nature Cell Biology 4, no. 9 (September 2002): 674–80. https://doi.org/10.1038/ncb836.